JP2017533946A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533946A5
JP2017533946A5 JP2017526527A JP2017526527A JP2017533946A5 JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5 JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017526527 A JP2017526527 A JP 2017526527A JP 2017533946 A5 JP2017533946 A5 JP 2017533946A5
Authority
JP
Japan
Prior art keywords
methyl
amino
carboxamide
pyrazine
oxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533946A (ja
JP6779204B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060509 external-priority patent/WO2016081290A1/en
Publication of JP2017533946A publication Critical patent/JP2017533946A/ja
Publication of JP2017533946A5 publication Critical patent/JP2017533946A5/ja
Application granted granted Critical
Publication of JP6779204B2 publication Critical patent/JP6779204B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526527A 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物 Expired - Fee Related JP6779204B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081262P 2014-11-18 2014-11-18
US62/081,262 2014-11-18
PCT/US2015/060509 WO2016081290A1 (en) 2014-11-18 2015-11-13 Aminopyrazine compounds with a2a antagonist properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020138418A Division JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Publications (3)

Publication Number Publication Date
JP2017533946A JP2017533946A (ja) 2017-11-16
JP2017533946A5 true JP2017533946A5 (enExample) 2018-12-20
JP6779204B2 JP6779204B2 (ja) 2020-11-04

Family

ID=56014406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017526527A Expired - Fee Related JP6779204B2 (ja) 2014-11-18 2015-11-13 A2a拮抗薬特性を有するアミノピラジン化合物
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020138418A Withdrawn JP2020193211A (ja) 2014-11-18 2020-08-19 A2a拮抗薬特性を有するアミノピラジン化合物

Country Status (11)

Country Link
US (1) US10472347B2 (enExample)
EP (1) EP3220910B1 (enExample)
JP (2) JP6779204B2 (enExample)
KR (1) KR20170083136A (enExample)
CN (1) CN107106558A (enExample)
AU (1) AU2015350315B2 (enExample)
BR (1) BR112017010261A2 (enExample)
CA (1) CA2967944C (enExample)
MX (1) MX381180B (enExample)
RU (1) RU2727805C2 (enExample)
WO (1) WO2016081290A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
US11066413B2 (en) 2017-03-07 2021-07-20 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
BR112020000962A2 (pt) 2017-07-18 2020-07-14 Nuvation Bio Inc. compostos de 1,8-naftiridinona e usos dos mesmos
JP2020527588A (ja) * 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
CN111629728A (zh) 2017-08-31 2020-09-04 科尔沃斯制药股份有限公司 用于调节腺苷a2b受体和腺苷a2a受体的化合物和方法
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
US20200079793A1 (en) * 2018-08-31 2020-03-12 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての7-、8-及び10-置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
CN113939291A (zh) 2019-01-18 2022-01-14 诺维逊生物股份有限公司 1,8-萘啶酮化合物及其用途
BR112021013936A2 (pt) 2019-01-18 2021-09-21 Nuvation Bio Inc. Compostos heterocíclicos como antagonistas de adenosina
TW202128650A (zh) 2019-10-11 2021-08-01 德商拜耳動物保健有限公司 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物
CN111285798A (zh) * 2020-04-09 2020-06-16 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺盐酸盐的合成方法
CN111423364A (zh) * 2020-05-19 2020-07-17 阿里生物新材料(常州)有限公司 一种(3-环丙基吡啶-2-基)甲胺的合成方法
EP3929189A1 (en) * 2020-06-25 2021-12-29 Bayer Animal Health GmbH Novel heteroaryl-substituted pyrazine derivatives as pesticides
CN117157278A (zh) * 2021-03-23 2023-12-01 柏奥艾奇实验室公司 Nlrp3炎性体的抑制剂
BR112023019211A2 (pt) 2021-03-23 2023-11-28 Bioage Labs Inc Inibidores de inflamassoma nlrp3
US11787805B2 (en) 2022-01-28 2023-10-17 BioAge Labs, Inc. N-oxide inhibitors of NLRP3 inflammasome
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
US12516018B2 (en) * 2023-03-30 2026-01-06 Brandeis University Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
TW202547472A (zh) 2024-03-26 2025-12-16 美商百愛及生物醫藥公司 Nlrp3發炎體之抑制劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
SI1283839T1 (enExample) 2000-05-26 2005-08-31 Schering Corp
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
JP2006527770A (ja) 2003-06-18 2006-12-07 アストラゼネカ アクチボラグ Cb1モジュレーターとしての2−置換5,6−ジアリール−ピラジン誘導体
WO2005040151A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
EP2438041A4 (en) * 2009-06-01 2012-11-21 Merck Sharp & Dohme PYRAZINE-carboxamide-orexin receptor Antagonist

Similar Documents

Publication Publication Date Title
RU2017120853A (ru) Аминопиразиновые соединения со свойствами антагониста a2a
KR101819433B1 (ko) 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체
JP4672820B2 (ja) GABAα5リガンドとしての置換1,2,4−トリアゾロ[3,4−a]フタラジン誘導体
US9321756B2 (en) Azole compounds as PIM inhibitors
MX2011012345A (es) Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas.
CN111556871B (zh) 作为PDE1抑制剂的1H-吡唑并[4,3-b]吡啶
JP2016500073A5 (enExample)
JP2013527173A5 (enExample)
JP2013508404A5 (enExample)
CN120826403A (zh) Shp2抑制剂化合物及其应用
JP2017530960A5 (enExample)
RU2007101544A (ru) Антагонисты рецепторов высвобождающего гонадотропин гормона
JP2013508403A5 (enExample)
EP2424859A1 (en) Inhibitors of pi3 kinase and / or mtor
ME02802B (me) P2x7 modulatori
AU2011338389A1 (en) Bicyclic compounds as Pim inhibitors
JP2013508405A5 (enExample)
DK2491038T3 (da) Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
RU2015114936A (ru) Ингибиторы серин/треонинкиназы
KR101898364B1 (ko) 인돌린-2-온 및 1,3-다이하이드로-피롤로[3,2-c]피리딘-2-온 유도체
KR20150047609A (ko) 피리딘 유도체 및 의약
CN114502537A (zh) 突变型idh2抑制剂及其应用
RU2015125306A (ru) Новые соединения ингибиторы фосфодиэстеразы типа 10а
WO2026076218A1 (en) Mrgprx2 antagonists and methods of use thereof
RU2020134947A (ru) Производные конденсированной циклической мочевины в антагонист crhr2